Our findings reveal a nuanced interplay between Gal-9 expression and disease outcomes providing a deeper understanding into the underlying pathophysiology of IBD and highlighting the potential of immunomodulation as a therapeutic strategy. This evidence concerns the gene LGALS9 and inflammatory bowel disease.